Neuronostics is a multi-award winning medtech company based in Bristol, enhancing how neurological conditions, starting with epilepsy, are diagnosed and managed.
Epilepsy affects over 65 million people worldwide, yet one in three people wait years for a confirmed diagnosis. Traditional EEGs, the standard test for suspected epilepsy, often return inconclusive results, meaning patients face uncertainty, misdiagnosis and delays to treatment.
Our innovative technology, BioEP, is among the first clinically validated digital biomarkers designed to reveal features of epilepsy in EEGs that may appear ‘normal’ under traditional analysis.
BioEP is a clinical decision support tool that analyses EEG data to determine if the analysis supports epilepsy or suggests a differential diagnosis. In standard settings, BioEP generates a report within 15 minutes, including data upload, analysis and output, supporting faster decision making without altering workflow.
BioEP is a UKCA marked Class I medical device, actively used in over 20 NHS Trusts for clinical research and pilot studies. A major NHS contract with Nottingham University Hospitals NHS Trust supports paediatric development, and we are planning for international expansion through strategic partnerships in the US and other global health markets.
What sets us apart is platform potential. We are currently running three clinical trials. Our largest prospective trial is focused on exploring the clinical utility and accuracy of our technology in first seizure clinics, with the aim to reduce uncertainty and delays caused by inconclusive EEG results. Another is exploring prognosis, looking at how our technology could support predictions around treatment response and long-term outcomes. The third is centred on paediatrics, working with leading NHS partners to better understand and manage epilepsy in children. Finally, our first single site trial, which has finished recruitment and is due to close soon, explored how our technology could improve the confidence of clinician’s decisions when diagnosing epilepsy.
With ISO 13485 certification, a strong IP portfolio, expanding NHS adoption and clear regulatory pathways in multiple territories, we are building a clinically grounded platform for neurological care. Starting with epilepsy, we are scaling into the £3.5B+ global EEG diagnostics market, with the vision to transform how neurological conditions are diagnosed, monitored and managed worldwide.
